Top

Published in:

01-10-2010

Visual Dysfunction Associated with Diabetic Retinopathy

Authors: Gregory R. Jackson, Alistair J. Barber

Published in: Current Diabetes Reports | Issue 5/2010

Abstract

Diabetic retinopathy is a leading cause of blindness and is commonly viewed as a vascular complication of diabetes mellitus. However, diabetes mellitus causes visual dysfunction before the onset of clinically visible microvascular changes associated with diabetic retinopathy. Thus, viewing diabetic retinopathy more generally as a neurovascular disease may lead to an improved understanding of the mechanisms responsible for vision loss. This article reviews the impact of diabetes mellitus on inner and outer retinal visual and electrophysiologic function and advocates for a multimodal approach to the study of diabetic retinopathy.

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group [no authors listed]. Ophthalmology 1991, 98(5 Suppl):766–785.

Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115:1447–1449, 1449.e1441–1449.e1410.

Beck RW, Edwards AR, Aiello LP, et al.: Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009, 127:245–251.CrossRefPubMed

Aiello LP, Edwards AR, Beck RW, et al.: Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010, 117:946–953.CrossRefPubMed

Scott IU, Edwards AR, Beck RW, et al.: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860–1867.CrossRefPubMed

•• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al.: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117:1064–1077.e35. This article demonstrates ranibizumab in combination improves vision in patients with DME. It provides hope for treatments of DME that may preserve vision better than laser, which ablates the retina.CrossRefPubMed

Nguyen QD, Shah SM, Heier JS, et al.: Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009, 116:2175–2181.e1.CrossRefPubMed

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group [no authors listed]. Ophthalmology 1981, 88:583–600.

Bresnick GH: Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol 1986, 104:989–990.PubMed

10.

•• Gardner T, Abcouwer S, Antonetti D, et al.: Pathogenesis of diabetic retinopathy. Arch Ophthalmol 2010, in press. Gardner et al. present the case that DR should be viewed as a neurodegenerative disease much as other complications of diabetes such as neuropathy are viewed. A comprehensive approach to the study of DR is proposed that integrates the best of basic and translational research.

11.

Wolter JR: Diabetic retinopathy. Am J Ophthalmol 1961, 51:1123–1141.PubMed

12.

Barber AJ, Antonetti DA, Kern TS, et al.: The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005, 46:2210–2218.CrossRefPubMed

13.

Barber AJ, Lieth E, Khin SA, et al.: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998, 102:783–791.CrossRefPubMed

14.

Gastinger MJ, Kunselman AR, Conboy EE, et al.: Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci 2008, 49:2635–2642.CrossRefPubMed

15.

Parravano M, Oddone F, Mineo D, et al.: The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol 2008, 92:1656–1660.CrossRefPubMed

16.

Parikh R, Naik M, Mathai A, et al.: Role of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthalmol 2006, 54:17–22.CrossRefPubMed

17.

Sieving PA, Nino C: Scotopic threshold response (STR) of the human electroretinogram. Invest Ophthalmol Vis Sci 1988, 29:1608–1614.PubMed

18.

Aylward GW, Billson FA: The scotopic threshold response in diabetic retinopathy--a preliminary report. Aust N Z J Ophthalmol 1989, 17:369–372.CrossRefPubMed

19.

Caputo S, Di Leo MA, Falsini B, et al.: Evidence for early impairment of macular function with pattern ERG in type I diabetic patients. Diabetes Care 1990, 13:412–418.CrossRefPubMed

20.

Bresnick GH, Palta M: Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 1987, 105:929–933.PubMed

21.

Vadala M, Anastasi M, Lodato G, Cillino S: Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: a long-term follow-up. Acta Ophthalmol Scand 2002 80:305–309.CrossRefPubMed

22.

Bresnick GH, Palta M: Predicting progression to severe proliferative diabetic retinopathy. Arch Ophthalmol 1987, 105:810–814.PubMed

23.

van Dijk HW, Kok PH, Garvin M, et al.: Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009, 50:3404–3409.CrossRefPubMed

24.

Van Dijk HW, Verbraak FD, Kok PH, et al.: Decreased retinal ganglion cell layer thickness in type 1 diabetic patients. Invest Ophthalmol Vis Sci 2010, 51:3660–3665.CrossRefPubMed

25.

Cabrera DeBuc D, Somfai GM: Early detection of retinal thickness changes in diabetes using optical coherence tomography. Med Sci Monit 2010, 16:MT15–MT21.PubMed

26.

Takahashi H, Goto T, Shoji T, et al.: Diabetes-associated retinal nerve fiber damage evaluated with scanning laser polarimetry. Am J Ophthalmol 2006, 142:88–94.CrossRefPubMed

27.

Henson DB, Williams DE: Normative and clinical data with a new type of dark adaptometer. Am J Optom Physiol Opt 1979, 56:267–271.PubMed

28.

Greenstein VC, Thomas SR, Blaustein H, et al.: Effects of early diabetic retinopathy on rod system sensitivity. Optom Vis Sci 1993, 70:18–23.CrossRefPubMed

29.

Holopigian K, Seiple W, Lorenzo M, Carr R: A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1992, 33:2773–2780.PubMed

30.

Abraham FA, Haimovitz J, Berezin M: The photopic and scotopic visual thresholds in diabetics without diabetic retinopathy. Metab Pediatr Syst Ophthalmol 1988, 11:76–77.PubMed

31.

Holopigian K, Greenstein VC, Seiple W, et al.: Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:2355–2365.PubMed

32.

Mantyjarvi M: Colour vision and dark adaptation in diabetic patients after photocoagulation. Acta Ophthalmol (Copenh) 1989, 67:113–118.CrossRef

33.

Henson DB, North RV: Dark adaptation in diabetes mellitus. Br J Ophthalmol 1979, 63:539–541.CrossRefPubMed

34.

Pender PM, Benson WE, Compton H, Cox GB: The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology 1981, 88:635–638.PubMed

35.

Arden GB, Wolf JE, Tsang Y: Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res 1998, 38:1723–1729.CrossRefPubMed

36.

Harris A, Arend O, Danis RP, et al.: Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996, 80:209–213.CrossRefPubMed

37.

Holfort SK, Klemp K, Kofoed PK, et al.: Scotopic electrophysiology of the retina during transient hyperglycemia in type 2 diabetes. Invest Ophthalmol Vis Sci 2010, 51:2790–2794.CrossRefPubMed

38.

Verrotti A, Lobefalo L, Altobelli E, et al.: Static perimetry and diabetic retinopathy: a long-term follow-up. Acta Diabetol 2001, 38:99–105.CrossRefPubMed

39.

Bengtsson B, Heijl A, Agardh E: Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia 2005, 48:2494–2500.CrossRefPubMed

40.

Greenstein VC, Hood DC, Ritch R, et al.: S (blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. Invest Ophthalmol Vis Sci 1989, 30:1732–1737.PubMed

41.

Cho NC, Poulsen GL, Ver Hoeve JN, Nork TM: Selective loss of S-cones in diabetic retinopathy. Arch Ophthalmol 2000, 118:1393–1400.PubMed

42.

Agardh E, Stjernquist H, Heijl A, Bengtsson B: Visual acuity and perimetry as measures of visual function in diabetic macular oedema. Diabetologia 2006, 49:200–206.CrossRefPubMed

43.

Frost-Larsen K, Larsen HW: Macular recovery time recorded by nyctometry--a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. Results of a 5-year follow-up. Acta Ophthalmol Suppl 1985, 173:39–47.CrossRefPubMed

44.

Frost-Larsen K, Lund-Anderson C, Starup K: Macular recovery during onset and development of diabetic retinopathy in childhood and adolescence. Acta Ophthalmol (Copenh) 1989, 67:401–404.CrossRef

Title: Visual Dysfunction Associated with Diabetic Retinopathy
Authors: Gregory R. Jackson
Alistair J. Barber
Publication date: 01-10-2010
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 5/2010
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-010-0132-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Visual Dysfunction Associated with Diabetic Retinopathy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

The Role of Kidney-Pancreas Transplantation in Diabetic Kidney Disease

Virus Infections: Lessons from Pancreas Histology

Virus Infections and Type 1 Diabetes Risk

Immune Intervention in Children with Type 1 Diabetes

Islet Transplantation: Alternative Sites

Loss and Preservation of β-Cell Function: Two Treatment Regimes Targeting T or B Lymphocytes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page